Synthesis of PDDA Functionalized Reduced Graphene Oxide Decorated with Gold Nanoparticles and Its Electrochemical Response toward Levofloxacin
Source abstract
Abstract
In this work synthesis of water-dispersible reduced graphene oxide (rGO), decorated with gold nanoparticles (AuNPs), was carried out in the presence of poly(diallyldimethylammonium chloride) solution (PDDA). The as-prepared hybrid nanocomposite (Au/PDDA/rGO) was characterized using various surface, structural, and electrochemical analysis techniques, such as scanning electron microscopy (SEM), transmission electron microscopy (TEM), X-ray diffraction (XRD) and voltammetry. The electrochemical performance of Au/PDDA/rGO-modified glassy carbon electrode (GCE) was investigated by studying the voltammetric behavior with different concentrations of levofloxacin (LV). Under optimized experimental conditions, at the Au/PDDA/rGO/GCE it was found that the response is linearly proportional to the concentration of LV in the ranges of 1.0 × 10−5–2.0 × 10−4 and 2.0 × 10−4–8.0 × 10−4 mol L−1, with detection limit estimated to be 3.9 × 10−6 mol L−1. The fabricated sensor was successfully applied for determination of LV in pharmaceutical tablets. Additionally, investigation of the interaction between LV and RNA molecules has also been carried out.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrochemical sensors and biosensors · Electrochemical Analysis and Applications · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. 10.1126/science.110289610.1126/science.1102896 ↗
2. 10.1002/adfm.20090037710.1002/adfm.200900377 ↗
3. 10.1088/0957-4484/23/33/33570710.1088/0957-4484/23/33/335707 ↗
4. 10.1039/b512799h10.1039/b512799h ↗
5. 10.1021/la902961310.1021/la9029613 ↗
6. 10.1016/j.elecom.2010.01.00410.1016/j.elecom.2010.01.004 ↗
7. 10.1021/la100575g10.1021/la100575g ↗
8. 10.1002/elan.20120052410.1002/elan.201200524 ↗
9. 10.1007/s10800-013-0569-710.1007/s10800-013-0569-7 ↗
10. Silva · Intern. J. Life Sci. & Pharma Research · 2012 · 2 · 147
11. Aronson J. K. , Side effects of drugs annual 34: A worldwide yearly survey of new data in adverse drug reactions, p. 763, Elsevier, Amsterdam (2012).
12. 10.1007/s00228-003-0688-x10.1007/s00228-003-0688-x ↗
13. Hsiao · Ann. Pharmacother. · 2005 · 1 · 14610.1345/aph.1E285 ↗
14. Wilkes G. M. Ades T. B. , Consumers Guide to Cancer Drugs, p. 414, Jones & Bartlett Publishers, London (2004).
15. 10.1592/phco.22.9.789.3407410.1592/phco.22.9.789.34074 ↗
16. Ronald A. R. Low D. E. , Fluoroquinolone antibiotics: Milestones in drug therapy, p. 107, Birkhäuser Verlag, Basel (2003).
17. 10.1134/S106193481101021710.1134/S1061934811010217 ↗
18. 10.1155/2009/81625210.1155/2009/816252 ↗
19. 10.1093/chromsci/44.4.20510.1093/chromsci/44.4.205 ↗
20. 10.1016/S0731-7085(96)01890-010.1016/S0731-7085(96)01890-0 ↗
21. 10.1002/jccs.20070014210.1002/jccs.200700142 ↗
22. 10.1021/jf052445i10.1021/jf052445i ↗
23. 10.1016/S0039-9140(02)00245-X10.1016/S0039-9140(02)00245-X ↗
24. 10.1134/S102319351002005910.1134/S1023193510020059 ↗
25. 10.1016/j.snb.2012.08.01010.1016/j.snb.2012.08.010 ↗
26. 10.1016/j.snb.2013.11.03710.1016/j.snb.2013.11.037 ↗
27. 10.1016/j.aca.2003.08.01810.1016/j.aca.2003.08.018 ↗
28. 10.1016/j.snb.2014.06.08910.1016/j.snb.2014.06.089 ↗
29. 10.1007/s00604-006-0715-610.1007/s00604-006-0715-6 ↗
30. 10.2298/JSC0912467Z10.2298/JSC0912467Z ↗
31. 10.1016/j.electacta.2013.03.09210.1016/j.electacta.2013.03.092 ↗
32. 10.1016/j.elecom.2010.01.00410.1016/j.elecom.2010.01.004 ↗
33. 10.1016/0013-4686(87)80028-210.1016/0013-4686(87)80028-2 ↗
34. 10.1016/j.aca.2005.03.05410.1016/j.aca.2005.03.054 ↗
35. 10.1016/S0022-0728(79)80075-310.1016/S0022-0728(79)80075-3 ↗
36. 10.2116/analsci.22.69110.2116/analsci.22.691 ↗